: Its growth is currently driven by two blockbuster immunosuppressants, Skyrizi and Rinvoq , which are projected to reach peak sales exceeding those of its former lead drug, Humira.
For conservative investors, is a favored "forever stock" due to its consistent performance and dividend track record. medical stocks to buy
Despite early 2026 struggles with higher costs, is positioned for a rebound as it remains the largest commercial health insurer in the U.S.. : Its growth is currently driven by two
: The company plans to build six new manufacturing plants in the U.S. to meet surging demand. Skyrizi and Rinvoq
: Its Da Vinci system has performed over 20 million procedures, creating a massive "moat" through installed equipment and surgeon training.
The Health of Your Wealth: Top Medical Stocks for April 2026